Matinas BioPharma Inc. (MTNB) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Matinas BioPharma Inc.

    AMEX: MTNB · Real-Time Price · USD
    1.88
    -0.04 (-2.08%)
    At close: Sep 25, 2025, 3:59 PM
    2.04
    8.51%
    After-hours: Sep 25, 2025, 07:30 PM EDT

    Matinas BioPharma Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a 1.1M 3.19M 33.33K
    Cost of Revenue
    		 972K 14.49M 16.68M 781.49K
    Gross Profit
    		 -972K -13.39M -13.49M -748.16K
    Operating Income
    		 -20.16M -23.77M -24.59M -24.73M
    Interest Income
    		 n/a n/a n/a 3K
    Pretax Income
    		 -24.25M -22.94M -21M -23.28M
    Net Income
    		 -24.25M -22.94M -13.02M -21.17M
    Selling & General & Admin
    		 8.73M 10.37M 11.1M 10.18M
    Research & Development
    		 11.43M 14.49M 16.68M 14.58M
    Other Expenses
    		 -972K n/a -16.68M 122.87K
    Operating Expenses
    		 19.19M 24.86M 11.1M 24.77M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 24.59M 24.86M 27.78M 24.77M
    Income Tax Expense
    		 -80K n/a -7.98M -2.11M
    Shares Outstanding (Basic)
    		 4.87M 4.35M 4.34M 4.2M
    Shares Outstanding (Diluted)
    		 4.87M 4.35M 4.34M 4.2M
    EPS (Basic)
    		 -4.98 -5.28 -3 -5.04
    EPS (Diluted)
    		 -4.98 -5.28 -3 -5.04
    EBITDA
    		 -23.36M -22.82M -24.23M -24.45M
    EBIT
    		 -24.33M -23.77M -24.59M -24.73M
    Depreciation & Amortization
    		 972K 941K 898K 781.49K

    Add to Watchlist